CD133 CAR-T局部治疗结合放化疗在MGMT启动子甲基化阴性新诊断胶质母细胞瘤患者中的安全性及有效性的1期临床研究 CD133 CAR-T júbù zhìliáo jiéhé fàng huàliáo zài MGMT qǐdòng zǐ jiǎ jī huà yīnxìng xīn zhěnduàn jiāo zhí mǔ xìbāo liú huànzhě zhōng de ānquán xìng jí yǒuxiào xìng de 1 qī línchuáng yánjiū 60 / 5,000 A phase 1 clinical study on the safety and efficacy of CD133 CAR-T local therapy combined with chemoradiotherapy in patients with newly diagnosed glioblastoma with negative MGMT promoter methylation

Sun Yat-sen University Cancer Center

Glioblastoma

Therapy Study

Premarket

Efficacy and safety of tislelizumab plus anlotinib in the treatment of cervical cancer resistant to standard therapy: A prospective, single-arm, open labelled phase II clinical trial

Sun Yat-Sen University Cancer Center

Diagnostic Accuracy Test

Post-market

Efficacy and safety of tislelizumab plus anlotinib in the treatment of cervical cancer resistant to standard therapy: A prospective, single-arm, open labelled phase II clinical trial

Diagnostic Accuracy Test

Post-market

Microwave ablation versus Radiofrequency ablation for solitary hepatocellular carcinoma up to 5 cm: A 10-year comparative analysis

Anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinoma (A-Plus): a phase II, single-arm, prospective study

Sun Yat-sen University Cancer Center

epithelial ovarian or peritoneal carcinoma

Therapy Study

Post-market

Dig deep learning based on 3D - CNN lung nodules with primary malignant tumor of multi-source CT imaging characteristics of constructing multi-dimensional model of qualitative diagnosis of pulmonary nodules

Sun Yat-Sen University cancer center

Therapy Study

Premarket

Phase I/ II clinical study of TAS-102 in combination with Fruquintinib and Sintilimab treat in patients with micro-satellite stable metastatic Colorectal cancer who have failed standard therapy

Sun Yat-sen University Cancer Center

Colorectal cancer

Diagnostic Accuracy Test

Post-market

Efficacy and Safety Analyses of Regorafenib with PD-1/PD-L1 Inhibitors versus Regorafenib alone as Second-line Treatment for Hepatocellular Carcinoma

Sun Yat-sen University Cancer Center

Hepatocellular carcinoma

Therapy Study

Post-market

A single arm phase II trial to evaluate the efficacy and safety of Surufatinib combined CAPTEM（Capecitabine plus Temozolomide）regimen for patients with advanced neuroendocrine tumors

Sun Yat-sen University Cancer Center

Neuroendocrine tumors

Therapy Study

Post-market

Safety and efficacy of histone deacetylase inhibitors (chidamide) in combination with abiraterone in the treatment of metastatic castration-resistant prostate cancer (mCRPC): a single-arm, open phase, Ib clinical study study

Diagnostic Accuracy Test

Post-market